Overview

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Status:
Not yet recruiting

Trial end date:
2029-07-31

Target enrollment:

Participant gender:

Summary

The purpose of this study to determine whether switching treatment earlier in the disease process will increase the amount of time that a patient's metastatic breast cancer is controlled compared to patients with metastatic breast cancer who receive treatment later based on diagnostic imaging results or other methods currently used in medical practice.

Phase:

Phase 2

Details

Lead Sponsor:

University of Miami

Treatments:

Anastrozole
Aromatase Inhibitors
Capecitabine
Elafin
Estrogen Receptor Modulators
Estrogens
Everolimus
Exemestane
Fulvestrant
Letrozole
Palbociclib
Selective Estrogen Receptor Modulators
Sirolimus
Tamoxifen
Vinorelbine